Abstracts tagged "Abatacept"

Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Hermine I. Brunner¹, N Ruperto², G Vega-Cornejo³, A Berman⁴, Inmaculada Calvo⁵, R Cuttica⁶, F Ávila-Zapata⁷, Michael Henrickson¹, DJ Kingsbury⁸, D Viola⁹, V Keltsev¹⁰, K Minden¹¹, John F. Bohnsack¹², X Li¹³, M Nys¹⁴, R Wong¹³, S Banerjee¹³, Daniel J Lovell¹ and Alberto Martini¹⁵, ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁷Star Medica Hospital, Yucatán, Mexico, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹CAICI Institute, Rosario City, Santa Fe State, Argentina, ¹⁰GBUZ Samara region "Togliatti City Clinical Hospital No.5" Rheumatology Department, Togliatti, Russian Federation, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²University of Utah School of Medicine, Salt Lake City, UT, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…
Abstract Number: 540 • 2017 ACR/ARHP Annual Meeting
Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Nobunori Takahashi, Toshihisa Kojima, Shuji Asai, Tatsuo Watanabe, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue and Naoki Ishiguro, Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Gwenny M. Verstappen¹, Johan Bijzet¹, Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Arjan Vissink², Hendrika Bootsma¹ and Frans G.M. Kroese¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…
Abstract Number: 2891 • 2017 ACR/ARHP Annual Meeting
Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Data on the association between RA and type 2 diabetes mellitus (T2DM) are inconsistent, suggesting RA treatments such as glucocorticoids (GCs) and hydroxychloroquine could…
Abstract Number: 608 • 2017 ACR/ARHP Annual Meeting
Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study
Philip J Mease¹, Iain B. McInnes², Vibeke Strand³, O FitzGerald⁴, H Ahmad⁵, A Johnsen⁵, J Ye⁵ and S Banerjee⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Stanford University, Palo Alto, CA, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, significantly increased ACR20 response and had an overall beneficial effect on musculoskeletal symptoms in patients with active psoriatic…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…
Abstract Number: 609 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial
Iain B. McInnes¹, Gianfranco Ferraccioli², MA D'Agostino³, M Le Bars⁴, S Banerjee⁵, H Ahmad⁵, Y Elbez⁶, J Ye⁵ and Philip J Mease⁷, ¹University of Glasgow, Glasgow, Great Britain, ²Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Hôpital Ambroise Paré, Boulogne-Billancourt, France, ⁴Bristol-Myers Squibb, Rueil-Malmaison, France, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Excelya, Boulogne-Billancourt, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Obesity is a risk factor for the development and severity of psoriatic arthritis (PsA).1,2 Patients (pts) with increased BMI (overweight/obese) are less likely to…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
Abstract Number: 1429 • 2017 ACR/ARHP Annual Meeting
Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
D Fleming¹, TA Simon¹, A Torbeyns², U Meier-Kriesche¹ and A Johnsen¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Braine l’Alleud, Belgium
Background/Purpose: Patients with RA have a 1.5–2-fold increased risk of mortality compared with the general population. The association between mortality rates and different RA treatments…
Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting
Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Rieke Alten¹, HM Lorenz², X Mariette³, HG Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen, Nürnberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Rieke Alten¹, H-M Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, L Bessette², E Alemao³, B Haraoui⁴, F Massicotte¹, M Mtibaa⁵, E Muratti⁵, Jean-Pierre Pelletier¹, R Postema⁶, Jean-Pierre Raynauld⁷, M-A Rémillard⁸, D Sauvageau¹, A Turcotte⁹, É Villeneuve¹ and L Coupal¹⁰, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Bristol-Myers Squibb, Montréal, QC, Canada, ⁶Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁸Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ¹⁰Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…
Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, Rolando Cimaz⁵, V Stanevica⁶, Gerd Horneff⁷, John F. Bohnsack⁸, Thomas A. Griffin⁹, R Carrasco¹⁰, Maria Trachana¹¹, Jason A Dare¹², I Foeldvari¹³, Richard K Vehe¹⁴, TA Simon¹⁵, Hermine I. Brunner¹⁶ and Alberto Martini², ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Cleveland Clinic, Cleveland, OH, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas for Medical Sciences, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, K Price³, S Kelly³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.